Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

NCT ID: NCT01107236

Last Updated: 2022-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety of IW-6118 when administered as a single oral dose to patients undergoing third molar extraction. Efficacy will be assessed in an exploratory manner.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IW-6118

Group Type EXPERIMENTAL

IW-6118

Intervention Type DRUG

Single dose

Placebo

Group Type PLACEBO_COMPARATOR

Matching Placebo

Intervention Type DRUG

Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium

Naproxen Sodium

Group Type ACTIVE_COMPARATOR

Naproxen Sodium

Intervention Type DRUG

Single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IW-6118

Single dose

Intervention Type DRUG

Matching Placebo

Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium

Intervention Type DRUG

Naproxen Sodium

Single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 18 and 30 years old at time of screening;
* BMI \> 18.5 and \< 30.0;
* In overall good health with no clinically-significant laboratory, ECG, or physical exam findings;
* Patient requires two ipsilateral third molar extractions of which one must be a full or partial bony mandibular impaction;
* Women of childbearing potential must have a negative pregnancy test and must agree to use double-barrier contraception;

Exclusion Criteria

* History of any clinically-significant medical condition;
* Previous usage of prescription, OTC, or investigational drugs as per protocol requirements;
* Inadequate levels of pain to be included in the study;
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ironwood Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ironwood Investigational Site

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ICP-109-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.